Eli Lilly Beats Quarterly Estimates and Raises Outlook on Zepbound and Mounjaro Sales
Eli Lilly on Thursday reported first-quarter earnings and revenue that blew past estimates, as demand for its blockbuster weight loss drug Zepbound and diabetes...